Invention Grant
US09428464B2 Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
有权
犬奈宁-3-单加氧酶抑制剂，药物组合物及其使用方法
- Patent Title: Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
- Patent Title (中): 犬奈宁-3-单加氧酶抑制剂，药物组合物及其使用方法
-
Application No.: US14241699Application Date: 2012-08-28
-
Publication No.: US09428464B2Publication Date: 2016-08-30
- Inventor: Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson , Celia Dominguez , Leticia M. Toledo-Sherman , Ignacio Muñoz-Sanjuan
- Applicant: Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson , Celia Dominguez , Leticia M. Toledo-Sherman , Ignacio Muñoz-Sanjuan
- Applicant Address: US NY New York
- Assignee: CHDI Foundation, Inc.
- Current Assignee: CHDI Foundation, Inc.
- Current Assignee Address: US NY New York
- Agency: Sheppard Mullin Richter & Hampton LLP
- International Application: PCT/US2012/052617 WO 20120828
- International Announcement: WO2013/033068 WO 20130307
- Main IPC: C07D239/52
- IPC: C07D239/52 ; A61K31/506 ; C07D239/28 ; C07D403/12 ; C07D403/06 ; C07D405/12 ; C07D413/12 ; C07D491/048 ; C07D239/42 ; C07D401/04 ; C07D401/12 ; C07D417/12 ; C07D471/04 ; C07D487/04
Abstract:
Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
Public/Granted literature
- US20140329795A1 KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF Public/Granted day:2014-11-06
Information query
